COSENTYX DRUG MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)

Cosentyx Drug Market, By Route of Administration (Subcutaneous injection and Intravenous infusion), By Indication (Hidradenitis suppurativa, Psoriatic arthritis, Ankylosing spondylitis, Plaque Psoriasis, and Others), By Distribution Channel (Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

In October 2023, Novartis AG, a global leader in immuno-dermatology and rheumatology, announced that the U.S. Food and Drug Administration (FDA) had approved Cosentyx (secukinumab) for the treatment of moderate to severe hidradenitis suppurativa (HS) in adults. Cosentyx is the only U.S. FDA-approved completely human biologic that directly inhibits interleukin-17A (IL-17A), a cytokine thought to be involved in the inflammation of HS.
In October 2023, Novartis AG, a global leader in immuno-dermatology and rheumatology, announced that the U.S. FDA had approved an intravenous (IV) formulation of Cosentyx (secukinumab) for the treatment of adults with psoriatic arthritis (PsA), ankylosing spondylitis (AS), and non-radiographic axial spondyloarthritis (nr-axSpA)
In December 2021, Novartis AG, a global leader in immuno-dermatology and rheumatology, announced that the U.S. FDA had approved Cosentyx (secukinumab) for the treatment of active enthesitis-related arthritis (ERA) in patients four years and older, and active psoriatic arthritis (PsA) in patients two years or older

Cosentyx Drug Market Report Snapshots